Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 369

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Open access
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., Schmidinger, M., Suarez, C., Teoh, J., de Velasco, G., Young, M., Gillessen, S.·2024·Annals of Oncology
DOI 10.1016/j.annonc.2024.05.537
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2024.05.537

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 70 references

Research works printed but not linked: 8

  1. Leveridge, 2011, Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy, Eur Urol, 60, 578, 10.1016/j.eururo.2011.06.021 · doi:10.1016/j.eururo.2011.06.021
  2. Widdershoven, 2021, Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up, Abdom Radiol (NY), 46, 373, 10.1007/s00261-020-02613-4 · doi:10.1007/s00261-020-02613-4
  3. Lardas, 2016, Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus, Eur Urol, 70, 265, 10.1016/j.eururo.2015.11.034 · doi:10.1016/j.eururo.2015.11.034
  4. Motzer, 2021, Nivolumab + cabozantinib (NIVO+ CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER, J Clin Oncol, 39, 308, 10.1200/JCO.2021.39.6_suppl.308 · doi:10.1200/jco.2021.39.6_suppl.308
  5. Powles, 2020, 718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment, Ann Oncol, 31
  6. Albiges, 2023, CaboPoint: interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC), J Clin Oncol, 41, 606, 10.1200/JCO.2023.41.6_suppl.606 · doi:10.1200/jco.2023.41.6_suppl.606
  7. Guillaume, 2022, Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: a multicentric retrospective study, Cancers (Basel), 14, 1678, 10.3390/cancers14071678 · doi:10.3390/cancers14071678
  8. Powles, 2022, Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma, J Clin Oncol, 40, 350, 10.1200/JCO.2022.40.6_suppl.350 · doi:10.1200/jco.2022.40.6_suppl.350

Cited by

See all 369

Metadata

Authors
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., Schmidinger, M., Suarez, C., Teoh, J., de Velasco, G., Young, M., & Gillessen, S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2024-08
Volume
35
Issue
8
Pages
692-706
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2024.05.537
OpenAlex
W4398213922
Cited by
369
References
70
FWCI
94.15
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • Kids Cancer Alliance
  • Kasturba Medical College, Manipal
  • European Society for Medical Oncology
  • Merck
  • EUSA Pharma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1016/j.annonc.2024.05.537
The paper
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., Kitamura, H., McKay, R., Porta, C., Procopio, G., Schmidinger, M., Suarez, C., Teoh, J., de Velasco, G., Young, M., & Gillessen, S. (2024). Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.05.537

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.